Optimi Health Sets US$15 Million 2.4 Million-Share Offering, Nasdaq Uplisting May 20
Optimi Health priced an oversubscribed US$15 million offering of 2.4 million shares at US$6.25, with a 360,000-share overallotment option. Shares begin trading on the Nasdaq Capital Market under OPTH on May 20 after a 1-for-30 consolidation, with net proceeds funding production scale and U.S. market expansion.
1. Offering Details
Optimi Health announced the pricing of its public offering of 2,400,000 common shares at US$6.25 per share, with the underwriter granted a 360,000-share overallotment option. The gross proceeds are expected to total US$15 million before fees, with closing anticipated on or about May 21, 2026.
2. Nasdaq Uplisting and Share Consolidation
Following a 1-for-30 share consolidation effective May 19, 2026, Optimi’s common shares will begin trading on the Nasdaq Capital Market under the symbol OPTH on May 20, 2026. The consolidation reduced the share count to approximately 3,225,881 shares issued and outstanding prior to the offering.
3. Use of Proceeds
Net proceeds from the offering will be used to scale production and distribution of psychedelic drug products in existing markets, support U.S. market expansion, and provide general working capital and operating expenses, with management retaining broad discretion over specific allocations.